162 related articles for article (PubMed ID: 37100777)
81. Prognostic Signature and Discrimination Signature of Lung Adenocarcinoma based on Pyroptosis-Related Genes.
Li GS; Lu HP; Gao L; Li JD; He RQ; Zhou HF; Chen SW; Liu J; Fu ZW; Kong JL; Zeng JH; He J; Chen G
Comb Chem High Throughput Screen; 2023; 26(2):347-361. PubMed ID: 35593363
[TBL] [Abstract][Full Text] [Related]
82. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
83. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
84. Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma.
Zhang Y; Zhang X; Lv X; Zhang M; Gao X; Liu J; Xu Y; Fang Z; Chen W
Biomed Res Int; 2020; 2020():1836542. PubMed ID: 33195688
[TBL] [Abstract][Full Text] [Related]
85. Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma.
Tang Y; Jiang Y; Qing C; Wang J; Zeng Z
Aging (Albany NY); 2020 Dec; 13(1):794-812. PubMed ID: 33340396
[TBL] [Abstract][Full Text] [Related]
86. Identification of a novel glycolysis-related gene signature for predicting metastasis and survival in patients with lung adenocarcinoma.
Zhang L; Zhang Z; Yu Z
J Transl Med; 2019 Dec; 17(1):423. PubMed ID: 31847905
[TBL] [Abstract][Full Text] [Related]
87. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
88. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
89. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
90. Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma.
Yang Y; Huang T; Fan Y; Lu H; Shao J; Wang Y; Shen A
Biomed Res Int; 2022; 2022():1753563. PubMed ID: 36389112
[TBL] [Abstract][Full Text] [Related]
91. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
Liu J; Wu H; Gao Z; Lou M; Yuan K
Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
[TBL] [Abstract][Full Text] [Related]
92. A seven-gene prognostic signature predicts overall survival of patients with lung adenocarcinoma (LUAD).
Al-Dherasi A; Huang QT; Liao Y; Al-Mosaib S; Hua R; Wang Y; Yu Y; Zhang Y; Zhang X; Huang C; Mousa H; Ge D; Sufiyan S; Bai W; Liu R; Shao Y; Li Y; Zhang J; Shi L; Lv D; Li Z; Liu Q
Cancer Cell Int; 2021 Jun; 21(1):294. PubMed ID: 34092242
[TBL] [Abstract][Full Text] [Related]
93. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
[TBL] [Abstract][Full Text] [Related]
94. Establishment and validation of an eight-gene metabolic-related prognostic signature model for lung adenocarcinoma.
Ma W; Liang J; Liu J; Tian D; Chen Z
Aging (Albany NY); 2021 Feb; 13(6):8688-8705. PubMed ID: 33619235
[TBL] [Abstract][Full Text] [Related]
95. The DDR-related gene signature with cell cycle checkpoint function predicts prognosis, immune activity, and chemoradiotherapy response in lung adenocarcinoma.
Li Q; Zhang P; Hu H; Huang H; Pan D; Mao G; Hu B
Respir Res; 2022 Jul; 23(1):190. PubMed ID: 35840978
[TBL] [Abstract][Full Text] [Related]
96. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma.
Song J; Sun Y; Cao H; Liu Z; Xi L; Dong C; Yang R; Shi Y
Bioengineered; 2021 Dec; 12(1):5932-5949. PubMed ID: 34488540
[TBL] [Abstract][Full Text] [Related]
97. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
98. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
Wang H; Wang X; Xu L; Cao H; Zhang J
Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
[TBL] [Abstract][Full Text] [Related]
99. An eleven-gene risk model associated with lymph node metastasis predicts overall survival in lung adenocarcinoma.
Zhao Y; Shi W; Tang Q
Sci Rep; 2023 Apr; 13(1):6852. PubMed ID: 37100777
[TBL] [Abstract][Full Text] [Related]
100. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
